REG - Tissue Regenix Group - HPRA approval & distribution agreement in Spain

Tissue RegenixAnnouncement

30/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231030:nRSd6125Ra&default-theme=true

RNS Number : 6125R  Tissue Regenix Group PLC  30 October 2023

Tissue Regenix Group plc

('Tissue Regenix', the 'Company' or the 'Group')

 

HPRA approval & distribution agreement in Spain

 

HPRA approval to provide an Irish logistics hub for the distribution of
allograft products in the EU

New exclusive distribution agreement for Tissue Regenix's allograft products
in Spain

 

Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company,
announces that it has received approval from the Irish Health Products
Regulatory Authority ('HPRA'), allowing the Company to set up a logistics hub
in Ireland for the distribution of its allograft products within the European
Union ('EU').

 

The HPRA regulates medicines and devices in Ireland for the benefit of people
and animals, inspecting companies and facilities which test, make or
distribute health products to ensure that they comply with relevant standards
and legislation.

 

Tissue Regenix has also signed an exclusive distributor contract with Spineart
España SLU ('Spineart') for the distribution of its allograft products in
Spain. Spineart is a privately held medical device company that operates in
over 60 markets, focused on simplifying surgery by designing, developing and
promoting safe and efficient solutions to spine surgeons, operating room teams
and patients.

 

Daniel Lee, Chief Executive Officer of Tissue Regenix, commented: "Receiving
HPRA approval is a great step for Tissue Regenix, as it will provide a
logistics hub for the distribution of our allograft products to the European
market. Following this, we are delighted to be partnering with Spineart to
bring our allograft products to more customers in the EU. Spineart have a
large global footprint that we hope in time can be leveraged to bring our
products to more customers internationally."

 

For more information:

 

 Tissue Regenix Group plc                                           www.tissueregenix.com (http://www.tissueregenix.com)
 David Cocke, Chief Financial Officer                               via Walbrook PR

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)
 Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
 Nigel Birks/Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)                                  Tel: +44 (0)20 7933 8780
 Alice Woodings                                                     TissueRegenix@walbrookpr.com (mailto:TissueRegenix@walbrookpr.com)

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries, and
wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This
biotech company specialises in regenerative medicine and is dedicated to
developing high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's human
tissue products may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKZMZGVNLGFZM